Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized

Carisma Therapeutics Inc.

2024-Q1 EPS reported -$0.46 revenue$3,400,000

Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.
Cash $56.5M as of March 31, 2024; expected to fund operations into Q3 2025.
Pipeline reprioritization: CT-0525 becomes lead; CT-0508 enrollment ceased; CT-1119 paused; workforce reduced ~37%.
Initial CT-0525 Phase 1 data expected by year-end 2024; preclinical fibrosis data presented at ASGCT.
Appointed Eugene Kennedy as CMO; John Hohneker to Board; Chidozie Ugwumba resigned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Carisma Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-059130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.